DexCom (XSWX:DXCM) Moat Score: 7/10 (As of Jun. 26, 2026)


XSWX:DXCM DexCom Inc XSWX:DXCM
90 GF Score
Price CHF56.54
GF Value CHF85.31
! 3 Warning Signs
View Full Analysis

What is DexCom Moat Score?

DexCom XSWX:DXCM 90 Moat Score is 7 as of Jun. 26, 2026. GuruFocus rates XSWX:DXCM with a GF Score™ of 90/100 and a GF Value™ of CHF85.31. The stock has 3 warning signs investors should review. Among 846 Medical Devices & Instruments companies, DexCom ranks better than 98.94% on this metric.

DexCom has the Moat Score of 7, which implies that the company might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

DexCom has Wide Moat: DexCom has a strong position in continuous glucose monitoring with significant intellectual property and high customer switching costs. Its brand is trusted in the healthcare sector, and it benefits from regulatory barriers and consistent innovation, supporting durable competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes DexCom might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

DexCom  (XSWX:DXCM) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

DexCom Moat Score Related Terms

XSWX:DXCM vs GEHC, STE, ZBH: Moat Score Comparison

For the Medical Devices subindustry, DexCom's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DexCom Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, DexCom's Moat Score distribution charts can be found below:

* The bar in red indicates where DexCom's Moat Score falls into.


XSWX:DXCM
90GF Score
DexCom Inc XSWX:DXCM
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 7 mean?
DexCom (XSWX:DXCM) has a Moat Score of 7 as of Jun. 26, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, DexCom ranks #9 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 1.1%.
Is DexCom's Moat Score too high?
DexCom's current Moat Score is 7. Based on the distribution chart, DexCom ranks #9 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, DexCom has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does DexCom's Moat Score compare to GEHC and STE?
According to the Medical Devices & Instruments industry distribution chart, DexCom ranks #9 out of 846 companies for Moat Score. This places DexCom in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. DexCom's current Moat Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
DexCom (XSWX:DXCM) has a current Moat Score of 7. The stock's GF Value™ is CHF85.31, compared to a current price of CHF56.54 — trading 33.7% below its estimated fair value. The current Moat Score is 7. DexCom's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For DexCom (XSWX:DXCM), the current Moat Score is 7 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DexCom (XSWX:DXCM) Overvalued in 2026?

Based on GuruFocus' analysis, DexCom stock appears to be undervalued. The current stock price of CHF56.54 is trading 33.7% below its estimated GF Value™ of CHF85.31.

Key valuation signals for XSWX:DXCM:

  • Moat Score: 7
  • GF Value™: CHF85.31 vs. price of CHF56.54 (33.7% below fair value)
  • GF Score™: 90/100 with 3 warning signs

No single metric tells the full story. See the XSWX:DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DexCom Business Description

Address 6340 Sequence Drive, San Diego, CA, USA, 92121
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
90GF Score

Get the complete analysis for XSWX:DXCM

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF56.54
Price
CHF85.31
GF Value